A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1474-1483

  Pawlowski, Andrzej ^a   Källenius, Gunilla ^a,b   Svenson, Stefan B ^a,c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Coupling; Hapten; Saccharide protein conjugate; Vaccine

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; CARRIER PROTEINS AND BINDING PROTEINS; DEXTRAN; HAPTEN; SULFIDE;

AMINATION; ARTICLE; CHEMICAL BOND; DRUG CONJUGATION; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; PH; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REACTION ANALYSIS; REACTION TIME; VACCINE PRODUCTION;

DEXTRANS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; MODELS, CHEMICAL; POLYSACCHARIDES, BACTERIAL; PROTEINS; SULFIDES; TETANUS TOXOID; VACCINES; VACCINES, CONJUGATE;

EID: 0345391013     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00385-5     Document Type: Article

References (38)

1. Lindberg A.A., Karnell A., Weintraub A. The lipopolysaccharides of Shigella bacteria as a virulence factor. Rev Inf Dis. 13(Suppl. 4):1991;S279-S284.
2. Verheul A.F., Snippe H., Poolman J.T. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev. 57:1993;34-49.
3. Moxon E.R., Kroll J.S. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol. 150:1990;65-85.
4. Douglas R.M., Paton J.C., Duncan S.J., Hansman D.J. Antibody responses to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 148:1983;131-137.
5. Avery O.T., Goebel W.F. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med. 50:1929;533-550.
6. Svenson S.B., Lindberg A.A. Oligosaccharide-protein conjugate: a novel approach for making Salmonella O-antigen immunogens. FEMS Microbiol Lett. 1:1977;145-148.
7. Svenson S.B., Lindberg A.A. Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup BO-antigen and characterization of the antibody response. J Immunol. 120:1978;1750-1757.
8. Jörbeck H.J., Svenson S.B., Lindberg A.A. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit opsonizing antibodies that enhance phagocytosis. Infect Immun. 32:1981;497-502.
9. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., Wenger J.D. Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA. 269:1993;221-226.
10. Fattom A., Shiloach J., Bryla D., Fitzgerald D., Pastan I., Karakawa W.W., Robbins J.B., Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid hydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun. 60:1992;584-589.
11. Taylor D.N., Trofa A.C., Sadoff J., Chu C., Bryla D., Shiloah J., Cohen D., Ashkenazi S., Lerman Y., Egan W., Schneerson R., Robbins J.B. Synthesis, characterization and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun. 61:1993;3678-3687.
12. Peeters C.C.A.M., Tenbergen-Meekes A.M., Evenberg D.E., Poolman K., Zegers B.J.M., Rijkers G.T.A. Comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol. 146:1991;4308-4314.
13. Seppälä I., Mäkelä O. Antigenicity of dextran-protein conju gates in mice: effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol. 143:1989;1259-1264.
14. Bergquist C., Lagergård T., Lindblad M., Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun. 63:1995;2021-2025.
15. Svenson S.B., Lindberg A.A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J Immunol Methods. 25:1979;323-335.
16. Gray G.R. Antibodies to carbohydrates: preparation of antigens by coupling carbohydrates to proteins by reductive amination with cyanoborohydride. Methods Enzymol. 50:1978;155-160.
17. Laferriére C.A., Sood R.K., de Muys J.M., Michon F., Jennings H.J. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine. 15:1997;179-186.
18. Anderson P.W., Pichichero M.E., Stein E.C., Porcell S., Betts R.F., Connuck D.M., Korones D., Insel R.A., Zahradnik J.M., Eby R. Effect of oligosaccharide chain length, exposed terminal group and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM 197. J Immunol. 142:1989;2464-2468.
19. Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., Johnson C., Madore D., Hogerman D. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J. 13:1994;368-372.
20. Gupta R.K., Egan W., Bryla D.A., Robbins J.B., Szu S.C. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun. 63:1995;2805-2810.
21. Gupta R.K., Szu S.C., Finkelstein R.A., Robbins J.B. Synthesis, characterization and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun. 60:1992;3201-3208.
22. Chu C., Liu B., Watson D., Szu S., Bryla D., Shiloach J., Schneerson R., Robbins J.B. Preparation, characterization and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun. 59:1991;4450-4458.
23. de Velasco E.A., Verheul A.F.M., Veeneman G.H., Gomes L.J.F., van Boom J.H., Verhoef J., Snippe H. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine. 11:1993;1429-1436.
24. Peeters C.C.A.M., Evenberg D., Hoogerhout P., Käyhty H., Saariner L., van Boekel C.A.A., van der Marel G.A., van Boom J.H., Poolman J.T. Synthetic trimer and tetramer of 3-β-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys. Infect Immun. 60:1992;1826-1833.
25. Svenson S.B., Nurminen M., Lindberg A.A. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun. 25:1979;863-872.
26. Einhorn M.S., Weinberg G.A., Anderson E.L., Granoff P.D., Granoff D.M. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet. 2:1986;299-302.
27. Vella P.P., Marburg S., Staub J.M., Kniskern P.J., Miller W., Hagopian A.I.C., Tolman L., Rusk C.M., Chupak L.S., Ellis R.W. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharides types 6B, 14, 19F and 23F and a meningococcal outer membrane protein complex. Infect Immun. 60:1992;4977-4983.
28. Daum R.S., Hogerman D., Rennels M.B., Bewley K., Malinoski F., Rothstein E., Reisinger K., Block S., Keyserling H., Steinhoff M. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis. 176:1997;445-455.
29. Gailit J. Restoring free sulfhydryl groups in synthetic peptides. Anal Biochem. 214:1993;334-335.
30. Kolodny N., Robey F.A. Conjugation of synthetic peptides to proteins: quantitation from S-carboxymethylcysteine released upon acid hydrolysis. Anal Biochem. 187:1990;136-140.
31. Askelöf P., Rodmalm K., Wrangsell G., Larsson U., Svenson S.B., Cowell J.L., Unden A., Bartfai T. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc Natl Acad Sci USA. 87:1990;1347-1351.
32. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem. 28:1956;350-356.
33. Habeeb A.F.S.A. Determination of free amino groups in proteins by trinitrobenzene-sulfonic acid. Anal Biochem. 14:1966;328-336.
34. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
35. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys. 82:1959;70-77.
36. Fattom A., Li X., Cho Y.H., Burns A., Hawwari A., Shepherd S.E., Coughlin R., Winston S., Naso R. Effect of conjugation methodology, carrier protein and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine. 13:1995;1288-1293.
37. Daum R.S., Hogerman D., Rennels M.B., Bewley K., Malinoski F., Rothstein E., Reisinger K., Block S., Keyserling H., Steinhoff M. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis. 176:1997;445-455.
38. Peeters C.C.A.M., Tenbergen-Meekes A.M.J., Poolman J., Zegers B.J.M., Rijkers G.T. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine. 19:1992;833-840.